FIELD: medicine.
SUBSTANCE: claimed adsorbent contains spherical activated carbon having size diameter of 0.01-1 mm, specific surface determined in accordance to Langmuir equation of 1000 m2/g or more, ratio of diffraction intensities R of 1.4 or more (R is determined as R = (I15-I35)/(I24-I35) (1), wherein I15 is diffraction intensity at diffraction angle (2θ) of X-ray diffraction is 15°C; I35 is diffraction intensity at diffraction angle (2θ) of X-ray diffraction is 35°C; I24 is diffraction intensity at diffraction angle (2θ) of X-ray diffraction is 24°C), and pore volume having diameter of 7.5-15000 nm is less than 0.25 mg/ml. In another embodiment claimed adsorbent contains abovementioned spherical activated carbon with modified surface. Also disclosed are pharmaceutical composition and method for prevention or treatment of kidney or liver diseases containing said adsorbent.
EFFECT: new adsorbent for peroral administration.
20 cl, 5 ex, 2 tbl, 12 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ADSORBENT FOR PERORAL ADMINISTRATION AND AGENT FOR TREATMENT OR PREVENTION OF KIDNEY OR LIVER DISEASES | 2003 |
|
RU2292211C2 |
| ORAL ADSORBENT AND AGENT FOR TREATMENT OR PREVENTION OF RENAL OR HEPATIC DISEASE | 2005 |
|
RU2396965C2 |
| ORALLY ADMINISTRATED ADSORBENT, THERAPEUTIC AGENT FOR KIDNEY DISEASE AND THERAPEUTIC AGENT FOR LIVER DISEASE | 2014 |
|
RU2632432C2 |
| ORAL ADSORBENT AND AGENT FOR TREATMENT OR PREVENTION OF RENAL OR HEPATIC DISEASE | 2005 |
|
RU2396964C2 |
| METHOD OF PRODUCING SPHERICAL ACTIVATED CARBON | 2005 |
|
RU2375302C2 |
| AGENT FOR ELIMINATION OF CIRCULAR DYSFUNCTION FACTOR | 2005 |
|
RU2362570C2 |
| METHOD OF PRODUCING ADSORBENT BASED ON ACTIVATED CARBON | 2020 |
|
RU2811471C2 |
| INDAZOLE DERIVATIVE SALTS AND THEIR CRYSTALS | 2017 |
|
RU2747399C2 |
| PENTACYCLIC COMPOUND SALT AND CRYSTAL THEREOF | 2020 |
|
RU2820938C2 |
| ADSORBENTS FOR ORAL ADMINISTRATION | 2012 |
|
RU2583934C2 |
